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BRIEF REPORT
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ABSTRACT
Staphylococcus aureus is implicated in disease progression in cutaneous T-cell lymphoma (CTCL). Here,
we demonstrate that malignant T cell lines derived from CTCL patients as well as primary malignant
CD4+ T cells from Sézary syndrome patients are considerably more resistant to alpha-toxin-induced cell
death than their non-malignant counterparts. Thus, in a subset of Sézary syndrome patients the ratio
between malignant and non-malignant CD4+ T cells increases significantly following exposure to alpha-
toxin. Whereas toxin-induced cell death is ADAM10 dependent in healthy CD4+ T cells, resistance to
alpha-toxin in malignant T cells involves both downregulation of ADAM10 as well as other resistance
mechanisms. In conclusion, we provide first evidence that Staphylococcus aureus derived alpha-toxin can
tilt the balance between malignant and non-malignant CD4+ T cells in CTCL patients. Consequently,
alpha-toxin may promote disease progression through positive selection of malignant CD4+ T cells,
identifying alpha-toxin as a putative drug target in CTCL.
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Introduction
Cutaneous T-cell lymphoma (CTCL) represents a group of non-
Hodgkin lymphomas characterized by the accumulation of clon-
ally expanded CD4+ T cells in the skin. Mycosis fungoides (MF)
is the most prevalent form and Sézary syndrome (SS) is an
aggressive leukemic variant of the disease.1 CTCL patients have
an increased risk of contracting severe infections compared to
healthy controls,2,3 which constitute amajor cause of death.4 The
most frequently found pathogen is Staphylococcus aureus
(S. aureus), infecting 44–76% of CTCL patients.5,6
In a murine CTCL disease model, it has been shown that
bacterial infections aggravate the disease7 and a reduction of
colonizing bacteria in CTCL patients with antibiotics has been
associated with clinical improvement and a decrease in tumour
burden.8,9 This suggests that S. aureus and its toxins fuel disease
progression (as reviewed in10). However, while the link between
bacterial infections and CTCL seems to persist, the underlying
mechanisms are a topic of ongoing discussion.
S. aureus produces a wide range of toxins that can be sub-
divided into three groups: super-antigens, pore-forming toxins
and exfoliative toxins.11 Previously, we have demonstrated that
super-antigens released by S. aureus can exacerbate CTCL by
stimulating non-malignant CD4+ T cells to produce growth
factors and cytokines, which in turn trigger activation and pro-
liferation of malignant cells.12,13 Despite the fact that the pore-
forming alpha-toxin is expressed by almost all S. aureus strains
(95%),11 its role in CTCL has not been investigated.
Alpha-toxin is secreted as a monomer and elicits its toxicity by
forming heptameric pores in the cell membrane. Its effect depends
on the toxin concentration, duration of exposure and cell type.14
The surface receptor for alpha-toxin is the disintegrin and metal-
loproteinase domain-containing protein 10 (ADAM10).15
Accordingly, surface expression levels of ADAM10 largely deter-
mine the toxin susceptibility of a given cell.16 However, while
ADAM10 levels are important, other mechanisms can further
modulate the susceptibility to alpha-toxin. For instance, multiple
lineages of cells are resistant to the alpha-toxin effects by blocking
pore formation, shedding or internalizing affected parts of the
membrane or by closing the pore itself.17–20
Here, we show in CTCL cell lines and primary cells from SS
patients that malignant CTCL cells are less sensitive to alpha-toxin
than their non-malignant CD4+ T cell counterparts. Our data
further show that resistance to alpha-toxin can be acquired through
multiplemechanisms including downregulation ofADAM10. This
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is the first study to show that alpha-toxin may tilt the balance
between malignant and non-malignant CD4+ T cells, favouring
the persistence of malignant over non-malignant CD4+ T cells.
Results
Malignant CTCL patient derived cell lines are resistant to
alpha-toxin induced cytotoxicity
We treated different malignant and non-malignant T cell lines
derived from CTCL patients with increasing concentrations of
alpha-toxin. Intriguingly, lactate dehydrogenase (LDH) release
and cell viability measurements revealed that all malignant cell
lines consistently exhibited either low sensitivity or complete
resistance to alpha-toxin-induced cell death at concentrations
where non-malignant cell lines were highly sensitive (Figure 1(a,
b) and Figure S2). Indeed, non-malignant T cell lines from CTCL
patients displayed a similar sensitivity to alpha-toxin as CD4+
T cells isolated from healthy donors (Figure 1(c,d), and Figure S2).
Alpha-toxin cytotoxicity is mediated by ADAM10 in
non-malignant CTCL cell lines and healthy CD4+ T cells
To determine if cell death was induced through alpha-toxin
binding to ADAM10, we pre-treated the non-malignant cell
line MyLa1850 with the ADAM10 inhibitor GI254023X
before toxin exposure, which effectively reduced cell death
(Figure 1(e,f)). ADAM10 specificity of the effect was verified
by targeted RNA interference in CD4+ T cells from healthy
donors prior to toxin exposure, which resulted in a similar
decrease in alpha-toxin sensitivity as with the pharmacological
inhibitor (Figure 1(g,h)).
Alpha-toxin selects for malignant CD4+ T cells in a subset
of SS patients
After establishing the difference in alpha-toxin susceptibility
between malignant and non-malignant T cell lines, we next
investigated whether this difference was also apparent in
Figure 1. Malignant CTCL cells are less sensitive to alpha-toxin than non-malignant CD4+ T cells. Cells were exposed to alpha-toxin before LDH release was measured
in the culture supernatant and/or viability was assessed by flow cytometry. (a,b) Malignant CTCL patient derived cell lines and the non-malignant CTCL cell lines MySi
and MyLa1850 (n = 3–5). (c,d) Purified primary CD4+ T cells from healthy donors and the malignant CTCL cell line, MyLa2059 (n = 2–4). (e,f) ADAM10 surface
expression and survival of MyLa1850 after alpha-toxin exposure following GI254023X treatment (n = 3). (g,h) Surface expression of ADAM10 of siRNA transfected
CD4+ T cells from healthy donors and survival after four days of toxin exposure (n = 2). Error bars display mean ± standard error of mean.
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primary malignant and non-malignant CD4+ T cells from SS
patients. SS patients are characterized by having high numbers
of circulating malignant T cells, identified by their monoclo-
nal T-cell receptor (TCR) and/or their low expression of CD7
and CD26.21 We analysed the survival of both malignant and
non-malignant CD4+ T cells from ten SS patients after treat-
ment with alpha-toxin (patient characteristics in
Supplementary Table 3). In cells from five of the ten SS
patients, we observed that the malignant CD4+ T cells were
more resistant to killing than the non-malignant CD4+ T cells
from the same patients (Figure 2(a)). Importantly, in the
patients in which the malignant cells exhibited resistance to
the toxin, the ratio of malignant to non-malignant CD4+
T cells was drastically increased following alpha-toxin expo-
sure (Figure 2(b)).
ADAM10 mediates alpha-toxin cytotoxicity in
non-malignant CD4+ T cells from SS patients
Similar to CD4+ T cells from healthy donors, cell death of non-
malignant CD4+ T cells was dependent on the expression of
ADAM10, as pharmacological inhibition of ADAM10 increased
the survival of these cells following treatment with alpha-toxin
(Figure 2(c)). In contrast, ADAM10 inhibition had no significant
Figure 2. Malignant cells from SS patients are less sensitive to alpha-toxin induced death than their non-malignant CD4+ counterparts. (a) Percentage viable
malignant and non-malignant CD4+ cells and (b) malignant to non-malignant CD4+ T cell ratio from SS patients normalized to untreated control (n = 10). (c) Survival
of non-malignant CD4+ T cells from SS patients after GI254023X pre-treatment followed by alpha-toxin treatment (n = 3). (d–f) Correlation of (d) alpha-toxin binding
versus ADAM10 receptors expression (p = .0002, R2 = 0.8412), (e) survival versus alpha-toxin binding (p = .2245, R2 = 0.178) and (f) survival versus ADAM10 surface
expression (p = .1404, R2 = 0.2508) of malignant CD4+ T cells from SS patients (n = 10). (g,h) ADAM10 surface expression and alpha-toxin binding of SS01 measured
with (g) flow cytometry or (h) confocal microscopy. Error bars display mean ± standard error of mean.
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effect on the survival of the malignant cells (Figure S3(a)).
Alpha-toxin binding correlated with ADAM10 surface expres-
sion in both malignant and non-malignant CD4+ T cells (Figure
2(d) and Figure S3(b–d)), consistent with ADAM10 being the
main receptor for alpha-toxin.15 Surprisingly, neither ADAM10
expression nor alpha-toxin binding correlated with the differ-
ences in alpha-toxin sensitivity of the malignant cells (Figure 2
(e,f)).
Nevertheless, in the patient with the greatest increase in the
malignant to non-malignant CD4+ T cell ratio following alpha-
toxin treatment (SS01), the malignant cells exhibited both
reduced ADAM10 expression and alpha-toxin binding com-
pared to the non-malignant CD4+ T cells (Figure 2(g)). This
was confirmed by confocal microscopy revealing almost com-
plete absence of alpha-toxin binding to malignant (TCRVβ18+)
cells, whereas non-malignant (TCRVβ18−) CD4+ T cells from
the same patient showed normal binding (Figure 2(h)).
ADAM10-independent resistance mechanisms against
alpha-toxin cytotoxicity
It has previously been shown that the toxic effects of alpha-toxin
can be evaded by internalisation of surface-bound toxin.17 To
investigate if this evasion mechanism is active in resistant CTCL
cells, we treated resistant malignant MyLa2059 and sensitive non-
malignant MyLa1850 cells with fluorescent-labelled alpha-toxin
and visualised its cellular localisation using confocal microscopy.
At 4°C, when internalisation machinery is inactive, the toxin
bound to the surface of both cell lines (Figure S4(a)). However,
at 37°C incubation, malignant MyLa2059 cells exhibited fluores-
cence patterns consistent with internalisation of the toxin,
whereas non-malignant MyLa1850 cells still only exhibited alpha-
toxin binding at the cell surface (Figure S4(a)). To test if blocking
internalisation could increase alpha-toxin sensitivity of the malig-
nant cells, we incubated peripheral blood monoculear cells
(PBMCs) from three SS patients with the clathrin-mediated endo-
cytosis inhibitor, Dynasore. Pre-treatment with Dynasore led to
a modest increase in toxin-induced cell death in the malignant
cells and subsequent decrease in the malignant to non-malignant
ratio in three patients, while the non-malignant CD4+ T cells were
not affected (Figure S4(b–d)).
Discussion
Bacterial colonization of lesional skin is common in CTCL
patients, with S. aureus being the most prevalent pathogen.4
Alpha-toxin is produced by essentially all S. aureus strains and
is able to induce apoptosis in T cells.11,22 However, the role of
alpha-toxin in CTCL has yet to be elucidated.
In this study, we were able to show that a variety of
malignant CTCL cell lines derived from patients suffering
from MF, SS and a CD30+ lymphoproliferative disease are
resistant to alpha-toxin, while non-malignant cell lines and
primary CD4+ T cells die through an ADAM10 dependent
mechanism. This was confirmed in primary cells from SS
patients where alpha-toxin favoured the survival of malignant
T cells over non-malignant CD4+ T cells in a subset of
patients by inducing death in the non-malignant CD4+
T cell population.
As in cell lines and CD4+ T cells from healthy donors,
ADAM10 surface expression determined the sensitivity of non-
malignant CD4+ T cells from SS patients towards the pore-
forming toxin. Malignant CD4+ T cells may develop resistance
to alpha-toxin through downregulation of ADAM10 expression,
as the case study of patient SS01 clearly showed. However, as
resistant malignant cells from other SS patients displayed normal
ADAM10 expression levels and alpha-toxin binding, ADAM10
downregulation cannot be the only resistance mechanism
employed by malignant CTCL cells. A possible mechanism
may be internalization of affected membrane areas. Dynasore
has previously been used to render resistant cells susceptible to
alpha-toxin induced cell death.17,23 As pre-incubation of SS
patient cells with the endocytosis inhibitor Dynasore prior to
toxin challenge led to an increase in cell death in the malignant
population, internalization of affected membrane parts might be
an additional mechanism contributing to reduced sensitivity of
the malignant cells towards the pore-forming toxin.
Here we show for the first time that malignant CTCL cells are
resistant to S. aureus derived alpha-toxin at concentrations
where non-malignant CD4+ T cells die. Consequently, the pre-
sence of alpha-toxin favours the persistence of malignant cells,
while removing the non-malignant CD4+ T cells. As such, this
study describes a new mechanism by which bacterial infections
may promote CTCL disease. Multiple resistance mechanisms
appear to be involved, including downregulation of ADAM10
surface expression and internalisation of surface bound alpha-
toxin. Given the prevalence of S. aureus colonisation in CTCL
skin lesions and their ubiquitous production of alpha-toxin, this
may explain why a reduction of bacterial infections by psoralen
and ultraviolet A (PUVA) and local or systemic antibiotic treat-
ment clinically improves CTCL.8,9,24 Indeed, it is possible that
the efficiency of PUVA treatment may rely on its anti-bacterial
effect and an interplay between skin resident dendritic and/or
malignant cells with non-malignant T cells12,13,25,26 and its mod-
ulation by alpha-toxin.
Neutralizing antibodies against alpha-toxin have passed
phase 1 clinical trials and are currently in phase 2b for the
treatment of ventilator-associated pneumonia.27 Our findings
suggest that alpha-toxin neutralizing antibodies could be bene-
ficial in the treatment of CTCL patients. A high incidence of
bacterial infections is not restricted to CTCL,28 and future stu-
dies should address if alpha-toxin may affect the functional
immune system without affecting malignant cells in other
types of skin cancers.
In conclusion, this study shows that alpha-toxin may con-
tribute to the pathology of CTCL by tilting the balance between
malignant CTCL cells and non-malignant CD4+ T cells,
strengthening the hypothesis that antibiotics are beneficial in
the treatment of CTCL.
Methods
Cell culture and isolation of PBMCs
CTCL cell lines were derived29–33 and maintained as stated in
Supplementary Table 1. PBMCs from healthy donors and SS
patients were isolated by Ficoll-based density-gradient centri-
fugation and CD4+ T cells were enriched using LS columns
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(Miltenyi Biotec, #130-041-306) and CD4 MicroBeads
(Miltenyi Biotec, #130-045-101) following the manufacturer`s
instructions. All work was performed in accordance with the
Declaration of Helsinki. Written informed consent of SS
patients was obtained after approval by the Committee on
Health Research Ethics (H-16025331).
Alpha-toxin treatment
Unlabelled alpha-toxin was obtained from List lab (#120),
while AF647 labelled alpha-toxin was conjugated as described
elsewhere.16,34 Cells were exposed to alpha-toxin for 6 hours
at 37°C, unless stated otherwise.
LDH activity assay
For LDH release assays (TaKaRa, #MK401), cells were grown
in RPMI 1640 (Gibco, #11835-063) or X-VIVO (Lonza,
#BE02-061Q) media without phenol red. LDH measurements
were normalized to maximum release induced by Triton
X-100 prior to subtracting the absorbance of the untreated
sample.
ADAM10 inhibition
Cells were pre-treated for 20 hours with 20 µM of the
ADAM10 inhibitor GI254023X (Sigma-Aldrich, #SML0789-
5MG) prior to toxin exposure.
Inhibition of ADAM10 internalisation using dynasore
Cells were pre-treated with the GTPase inhibitor Dynasore
(abcam, #120192) for 1 hour at 37°C prior to toxin treatment.
siRNA transfection
Cells were transfected with short interfering RNA (siRNA)
ON-TARGET plus smart pool against Human ADAM10
(Dharmacon, #L-004503-00-0005) using the Amaxa nucleo-
fectin technology. Briefly, cells were re-suspended in IngenioR
Electroporation Solution (Mirus, #MIR 50111) containing the
siRNA and then transfected with an Amaxa Nucleofector 1
apparatus (Amaxa), using the pulsing parameter U-14. In all
transfection experiments, the knockdown results were com-
pared to cells that had been transfected with ON-TARGET
plus non-targeting control siRNA (Dharmacon, #D-001810-
01-20). Cells were exposed to alpha-toxin five days after
transfection for a period of four days at 37°C.
Flow cytometry
Cell surface staining was performed in FACS-PBS (PBS + 1%
FBS + 0.02% NaN3) or Brilliant Stain Buffer (BD Bioscience,
#563794), using primary conjugated antibodies as listed in
Supplementary Table 2. Malignant cells were identified as
CD3+CD4+CD7− and CD26− and/or TCRVβ#+, as previously
described;35 representative examples are depicted in Figure S1.
Dead cells were excluded using Propidium iodide
(eBioscience, #MBS500PI) and/or Annexin V – FITC or PE
(BioLegend, #640945/#640908). To improve Annexin
V binding, cells were stained in Annexin V Binding Buffer
(BD Bioscience, #51-66121E). All flow cytometric analyses
were performed using a 3- or 5-laser BD LSR-Fortessa and
analysed using FlowJo (TreeStar) software.
Immunofluorescent microscopy
CTCL cell lines were incubated on ice for 30 minutes prior to
2 hours treatment with 1.5 µg/ml AF647 labelled alpha-toxin.
Cells were fixed in 2% PFA for 10 minutes at room tempera-
ture and permeabilised with ice-cold methanol. Nuclei were
stained with DAPI (ThermoFisher, #62248) prior to mounting
in SlowFade Diamond Antifade mountant (ThermoFisher,
#S36967).
Primary SS patient cells were incubated for 1 hour on ice
prior to 6 hours treatment with 1.5 µg/ml AF647 labelled
alpha-toxin on ice or at 37°C. Cells were stained with anti-
TCRVβ18 (Beckman Coulter, #IM2049) and fixed with Fix
Perm (BD, #554714) for 15 minutes at room temperature.
After nuclei staining with Hoechst-33342 (ThermoFisher,
#62249) for 10 minutes at room temperature, cells were
mounted in ProLong Diamond Antifade mounting media
(ThermoFisher, #P36965). All experiments were visualized
on a ZEISS LSM 710 and analysed using the ZEN 2.5 lite
software.
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